6 pending office actions • 4 clients
| Client (Assignee) | Pending OAs |
|---|---|
| AbbVie Inc. | 2 |
| Abbvie Biotechnology Ltd. | 2 |
| Syndesi Therapeutics SA | 1 |
| Neurocrine Biosciences, Inc. | 1 |
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18733551 | BROMODOMAIN INHIBITORS | AbbVie Inc. | CHEN, PO-CHIH | 1621 | Non-Final OA | Jun 04, 2024 |
| 18548014 | COMPOUND FOR TREATMENT OF COGNITIVE DISORDERS | Syndesi Therapeutics SA | DAHLIN, HEATHER RAQUEL | 1629 | Non-Final OA | Aug 25, 2023 |
| 18227643 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Biotechnology Ltd. | BRAUN, MADELINE E | 1624 | Non-Final OA | Jul 28, 2023 |
| 18227639 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Biotechnology Ltd. | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Jul 28, 2023 |
| 17733303 | IL-1 Binding Proteins | AbbVie Inc. | CANELLA, KAREN A | 1643 | Final Rejection | Apr 29, 2022 |
| 16105396 | Pharmaceutical Formulations for Treating Endometriosis, Uterine Fibroids, Polycystic Ovary Syndrome or Adenomyosis | Neurocrine Biosciences, Inc. | RODRIGUEZ, RAYNA B | 1628 | Final Rejection | Aug 20, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial